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Abstract
Background Despite common use, anticholinergic medications have been associated with serious health risks. Interventions 
to reduce their use are being developed and there is a need to understand their implementation into clinical care. Aim of 
review This systematic review aims to identify and analyse qualitative research studies exploring the barriers and facilitators 
to reducing anticholinergic burden. Methods Medline (OVID), EMBASE (OVID), CINAHL (EMBSCO) and PsycINFO 
(OVID) were searched using comprehensive search terms. Peer reviewed studies published in English presenting qualitative 
research in relation to the barriers and facilitators of deprescribing anticholinergic medications, involving patients, carers 
or health professionals were eligible. Normalization Process Theory was used to explore and explain the data. Results Of 
1764 identified studies, two were eligible and both involved healthcare professionals (23 general practitioners, 13 specialist 
clinicians and 12 pharmacists). No studies were identified that involved patients or carers. Barriers to collaborative work-
ing often resulted in poor motivation to reduce anticholinergic use. Low confidence, system resources and organisation of 
care also hindered anticholinergic burden reduction. Good communication and relationships with patients, carers and other 
healthcare professionals were reported as important for successful anticholinergic burden reduction. Having a named person 
for prescribing decisions, and clear role boundaries, were also important facilitators. Conclusions This review identified 
important barriers and facilitators to anticholinergic burden reduction from healthcare provider perspectives which can 
inform implementation of such deprescribing interventions. Studies exploring patient and carer perspectives are presently 
absent but are required to ensure person-centeredness and feasibility of future interventions.
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Impacts on practice
• Important personal and structural factors such as confi-
dence, time, inter-professional relationships and effec-
tive communication can influence engagement with, and 
success of, anticholinergic burden reduction initiatives 
and should be considered within the design of such initia-
tives.
• Given the limited published evidence, we recommend 
researchers, clinicians and service providers consider 
evaluating implementation issues when planning future 
anticholinergic deprescribing interventions.
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Introduction
Anticholinergic drugs, used to treat common conditions 
including gastrointestinal disorders, overactive bladder, 
depression, and cardiovascular disease [1–3], have many 
side effects including dry mouth, constipation, increased 
heart rate, and confusion [1, 2]. Estimates regarding the 
number of adults using one or more anticholinergic medi-
cations range considerably, from 11 to 47% [4–6]. Con-
comitant use of multiple medications with anticholinergic 
properties has a cumulative effect, known an anticholin-
ergic burden (ACB) [2, 7]. Greater ACB has been associ-
ated with impaired physical and cognitive function, falls, 
cardiovascular events and mortality [8–13]. Much of the 
present evidence behind these adverse events was deter-
mined from older persons; however, recent evidence sug-
gests use of anticholinergics in mid-life may pose similar 
risks in later life [13], especially its impact on cognitive 
impairment [14]. Given these significant risks, several 
interventions aimed at reducing ACB have been developed 
and tested. Our recent systematic review identified eight 
such studies (PROSPERO registration CRD42018089764) 
[15]. Interventions varied widely regarding their design 
and setting (e.g. community, nursing homes, acute care), 
person delivering the interventions (e.g. pharmacist, phar-
macologist, physician), and how recommendations were 
identified and made (e.g. face to face, over the telephone 
or virtually) [15]. Seven of the eight studies reported posi-
tive improvements regarding ACB [15]. However, little is 
known about the implementation of such interventions, for 
example what factors can increase or decrease successful 
embedding and integration of them into practice.
The literature surrounding the broader concept of 
‘deprescribing’ reveals common barriers and facilitators 
[16–19]. These include concerns about negative conse-
quences arising from stopping medications, and a lack 
of ongoing support [16–19]. Conversely, patient motiva-
tion, support for the prescriber and patient, and prescriber 
and patient beliefs, all support the deprescribing process 
[16–19]. However, it is unknown if the barriers and facili-
tators towards reducing ACB differ from those for general 
deprescribing of inappropriate medications. Anticholin-
ergic drugs and medical conditions associated with their 
use may present unique challenges. Understanding this is 
essential to inform the development and design of ACB 
reduction interventions, in line with the Medical Research 
Council (MRC) Complex Intervention Framework [20]. 
Addressing these factors will increase the chances of suc-
cessfully implementing interventions into practice [20] A 
robust theoretical framework to underpin our data analysis 
is also required to help us move from a descriptive account 
to one that is more explanatory, which is advocated when 
developing complex interventions [20]. NPT is a well-
developed theory for understanding the factors involved in 
successful implementation [21–25]. NPT consists of four 
constructs: coherence, which addresses the sense-making 
work that people participating in an intervention have to 
undertake; cognitive participation, the engagement work 
that is undertaken by or between participants; collective 
action, the operational work and tasks that people have to 
do to enact the intervention; and reflexive monitoring, the 
appraisal work people undertake in relation to the inter-
vention [24].
Aim of review
This study aims to identify facilitators and barriers to the 
implementation of interventions to reduce ACB amongst 
adult patients from the perspectives of healthcare profes-
sionals, patients and carers from the available qualitative 
evidence and through the lens of NPT. This review will seek 
to identify key research gaps where future implementation 
research is required.
Methods
The systematic review protocol is PROSPERO registered 
(CRD42018109084), published [26], conducted in line with 
the general principles of the Cochrane Handbook for Sys-
tematic Reviews of Interventions [27], ENTREQ (Enhanc-
ing Transparency in Reporting the Synthesis of Qualitative 
Research) [28] and reported in accordance with the PRISMA 
statement [29]. See Supplementary file 1 for further protocol 
detail and PRISMA checklist.
Search strategy and selection criteria
Four electronic databases were searched: Medline (OVID), 
EMBASE (OVID), CINAHL (EMBSCO) and PsycINFO 
(OVID). The search strategy developed for Ovid MED-
LINE was adapted for the other databases (presented in 
Supplementary material 1). Bibliographies and citations of 
included publications were searched manually for eligible 
studies. Inclusion/exclusion criteria were determined using 
a modified PICO (population, intervention, control and 
outcome) framework [30], presented in Table 1. Language 
exclusions were conducted by hand. No date restrictions 
were imposed.
Data collection and extraction
Searches were conducted on 2nd November 2018 and 
updated on the 31st March 2020. Identified studies were 
transferred into RefWorks (ProQuest LLC) [31] and then 
into Covidence (Veritas Health Innovation Ltd) [32] for 
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screening. Two independent reviewers (shared between CS, 
KG, AN, MC, RN, CB, PKM, DB) screened each article 
title, abstract and full text using the eligibility criteria. Study 
authors were contacted where full-texts could not be found. 
Discrepancies between two reviewers were resolved by a 
third reviewer (FSM).
A standardised data extraction form was developed. Study 
descriptives such as publication year, author, location, set-
ting etc. were collected alongside relevant qualitative data 
and information required to ascertain quality. Two reviewers 
(CS, KG) completed data extraction. Disagreements were 
discussed and resolved within the wider research team.
Quality assessment
Two reviewers (CS, KG) independently assessed risk of 
bias using the Critical Appraisal Skills Programme quali-
tative checklist (2018) checklist [33]. Quality assessments 
were used to describe reliability and validity of the body of 
evidence.
Analysis
Two reviewers (CS, KG) conducted data analysis with the 
wider research team available for arbitration. Qualitative 
data were exported into Microsoft Excel [34] to facilitate 
data analysis. Normalization Process Theory (NPT) served 
as the underpinning conceptual framework. A coding sheet 
underpinned by NPT was developed to provide a framework 
for categorising the data (see Supplementary file 1). This 
was adapted and refined during analysis and a note was taken 
of any data that fell outside of the framework.
Results
Identified studies were transferred to Covidence and after 
deduplication, 1764 studies remained. Following title and 
abstract screening, 38 articles were reviewed by full text 
and two articles met our inclusion criteria (exclusion rea-
sons shown in PRISMA Flowchart, Fig. 1). Both studies [35, 
36] were conducted in Australia and involved 48 healthcare 
professionals (23 General Practitioners (GP), 13 specialist 
clinicians (SP) and 12 accredited pharmacists (AP)). One 
study was exclusive to primary care [35] while the other 
spanned primary, community, and secondary care set-
tings [36]. Both studies specifically targeted older people 
[35, 36]. No studies included patients or carers as partici-
pants. The studies differed in their context. Gnjidic et al. 
[35] obtained feedback from GPs who had participated in 
an ACB reduction intervention. The study by Kouladjian 
et al. [36] asked about implementation hypothetically (par-
ticipants had not been involved in an intervention). In terms 
of design, the study reported by Gnjidic et al. [35] was a 
cluster randomized controlled trial and the qualitative data 
were obtained from GPs’ feedback, obtained through written 
or verbal communication. In the study by Kouladjian et al. 
[36] qualitative data were obtained through semi-structured 
interviews and focus groups. CASP assessment found that 
both studies reported clear aims and recruitment strategies 
and tackled a research question appropriate for qualitative 
Table 1  Study eligibility criteria
Inclusion criteria Exclusion criteria
Population (Participants) Persons aged ≥ 18 years of age
Persons using one or more anticholinergic medications
Carer/proxy (e.g. a person answering on behalf of the patient) for an adult using one or more 
anticholinergic medications
Healthcare professional (e.g. physicians, nurses, pharmacists) involved in the care of adults 
using one or more anticholinergic medications









Intervention Original research findings examining attitudes to deprescribing/medication switching in 
relation to anticholinergic medication
Study type/design Qualitative research (face-to-face or telephone approaches)




Outcome Barriers and facilitators to deprescribing or medication switching in relation to anticholiner-
gic medications
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research. However, several methodological concerns were 
evident (see Table 2). Both studies reported limited detail 
on data collection and analysis [35, 36].
Across the four NPT constructs we identified data that 
fell within 8 core themes and 19 sub-themes (illustrated in 
Table 3). No relevant data fell outside the NPT framework. 
Figure 2 presents the identified barriers and facilitators for 
illustrative purposes.
Coherence (Sense making)
This theme describes how participants make sense of and 
plan ACB reduction. The data depict what participants envi-
sion ACB reduction to look like (differentiation), how it is 
valued and what tasks it involves. We identified six facilita-
tors of ACB reduction; having a clear prompt for change, 
having someone take the lead, making it individualised, able 
to stop or reduce medications, being aware of the importance 
of ACB reduction, and believing patients desire ACB reduc-
tion. We also identified 3 barriers to ACB reduction; distrac-
tion from other clinical issues, limitations of roles (profes-
sional) and uncertainty about the value of ACB reduction.
There were several statements made in reference to how 
ACB reduction interventions acted as a clear prompt for 
change; an alert system of possible problems that was seen 
by some to be a useful approach to bringing potential prob-
lems to the forefront [36]. Converse to this, there were con-
cerns from some that an intervention focusing upon ACB 
may be a distraction from other clinical issues, such as other 
harmful medications without anticholinergic properties [36]. 
This appeared related to concerns about embedding ACB 
reduction interventions alongside clinical judgement about 
other aspects of care.
Many statements reflected a general understanding that 
ACB reduction involved stopping or reducing medication 
with anticholinergic properties through identifying problem 
medications or side effects [35, 36]. This task may be under-
taken by the individual (prescriber) or involve making rec-
ommendations to prescribers [36]. Many accounts reported 
the need for someone to be taking the lead in facilitating 
this, usually through collaborative communication with 
patients, family, carers, and other health professionals [36]. 
This leadership role required facilitating discussions, and 
negotiation, principally with patients and other health pro-
fessionals [36]. However, there were uncertainties as to who 
Fig. 1  PRISMA flowchart
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should lead in these conversations. An important aspect of 
ACB reduction indicated by several healthcare professionals 
is the need for individualisation, making it personalised for 
patients [36], weighing up an individual’s risks and benefits 
to reach the best recommendations for that patient [36].
Perceived limitations of their role was expressed as a 
barrier to supporting ACB reduction by participants. For 
some, particularly pharmacists, limitations came from rec-
ommendations not being followed by prescribers, leading 
to participants questioning the value of these attempts at 
ACB reduction [36]. For others, limitations in what they 
could achieve stemmed from a conflict in priorities between 
patient-centred care and the needs and wishes of the patient’s 
carer [36].
Participants demonstrated awareness of the importance 
of ACB reduction and understood the risks of anticholiner-
gic medications and why their use should be reviewed [35, 
36]. Two participants [36] perceived that ACB reduction 
was desired by patients, particularly older patients. How-
ever, there were also some uncertainties about the value of 
ACB reduction, often presented in relation to the need for 
individualisation [35, 36]; it was perceived by some that 
ACB reduction was not necessarily an achievable goal for 
all patients. Questioning the value was also framed through 
the participants’ lack of knowledge or confidence in relation 
to tackling perceived difficulties, such as long-term use of 
benzodiazepines.
Cognitive participation (Engagement)
This theme describes the relationship work involved in ACB 
reduction (enrolment), the qualities or characteristics of that 
work, who is involved, and relationship difficulties faced. We 
identified five barriers to ACB reduction; perceived lack of 
control, inadequate information sharing, resistance towards 
interdisciplinary working, unwelcome professional boundary 
crossing, and limited opportunities to participate in ACB 
reduction tasks.
The sense of low control over ACB reduction from par-
ticipants described earlier [36] was sometimes linked to poor 
inter-professional relationships and a barrier to engaging 
with relevant others to perform necessary tasks for ACB 
reduction. However, low control arising from structural 
or organisational issues were also cited. For example, the 
involvement of multiple providers made it difficult to control 
what a patient was being prescribed. This resonates with 
statements made referencing inadequate information shar-
ing, which impacted on ability to fully understand patients 
ACB and act upon it [36].
Several references were made to there being resistance 
to inter-disciplinary working between health professionals 
[35, 36]. Sometimes resistance was expressed in terms of 
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necessity for particular medications [36]. Many statements 
suggest concerns about unwelcome professional boundary 
crossing when several health professionals are involved in 
a patient’s care [35, 36]. It was perceived that recommen-
dations made by pharmacists were not always actioned by 
the GP. There were also concerns from GPs about chang-
ing medications prescribed by specialists. There was also 
confusion about the roles of different health professionals 
in regard to ACB reduction. Conflict may arise due to poor 
communication between health professionals, because there 
are often very limited opportunities to participate in multi-
disciplinary discussions regarding a patient’s medications 
[36]. This could be frustrating, leaving one party feeling 
aggrieved that their perspective has not been considered.
Collective action (Operationalising ACB reduction)
This theme describes the resources perceived to be needed 
for ACB reduction, organisational and environmental influ-
ences, and impact on workload. We identified two barriers to 
ACB reduction; low confidence in personal skills and system 
and resource influences.
Several participants raised concerns about how system 
and resource issues influence ACB reduction success [36]. 
These ranged from a lack of time in consultations, to health 
insurance systems which actively make it more difficult to 
reduce prescribing of some medications. The way health 
care systems operate was also raised as an additional chal-
lenge for those conducting reviews remotely from the pre-
scriber [36]. Several statements reported how participants 
were becoming frustrated at the lack of recommendations 
being upheld [36]. Participants across both studies reported 
low confidence in personal skills to tackle ACB and uncer-
tainties about how to address it were at times linked with 
doubts that it may not be the correct thing to do [35, 36].
Reflexive monitoring (Monitoring and appraising)
This theme describes the monitoring of patients before and 
after ACB reduction, and how the value of ACB reduction 
is determined through reflective practice. We identified two 
facilitators of ACB reduction; making ACB meaningful and 
reflective practice.
There were statements regarding the repetitive and itera-
tive nature of ACB reviews [36]. Participants reported how 
ACB reduction was trialled and then reviewed to evaluate 
the impact of any changes made [36]. It was this follow-up 
that allowed participants to evaluate how effective their rec-
ommendations had been, suggestive of reflective practice. 
Furthering the idea of reflective practice, several suggestions 
were made [36] regarding how making ACB reduction more 
meaningful could enhance ACB reduction. For example, 
some participants felt a numerical score would be easier 
to understand and engage patients with and would provide 
something measurable to evaluate success against.
Discussion
To the best of our knowledge, this is the first study to sys-
tematically review qualitative studies exploring the barriers 
and facilitators to ACB reduction. We identified two eligible 
Table 3  Overview of identified NPT themes, facilitators and barriers
NPT construct Core theme Facilitators Barriers
Coherence (Sense making) Differentiation Clear prompt for change Distraction from other clinical issues




Value Awareness of importance of addressing 
ACB
Patients desire ACB reduction
Uncertainty about value
Cognitive participation (Engagement) Enrolment Perceived lack of control
Inadequate information sharing
Resistance to interdisciplinary working
Unwelcome professional boundary 
crossing
Limited opportunities to participate
Collective action (Operationalising ACB 
reduction)
Skills Low confidence in personal skills
Contextual System and resource influences
Reflexive monitoring (Monitoring and 
appraising)
Reconfiguration Making ACB reduction more meaning-
ful
Appraisal Reflective practice
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studies [35, 36] which involved healthcare professionals 
only. Participants varied in their beliefs in relation to the 
need and value of ACB reduction, particularly in relation to 
its importance in comparison to other clinical issues. Dif-
ficulties in collaborative working often resulted in perceived 
low control and poor motivation. Concerns about personal 
knowledge and confidence, system resources and organisa-
tion of care were also raised as barriers. Good communica-
tion and working relationships with the patient, carer and 
other healthcare professionals were important for successful 
ACB reduction. Assigning responsibility for prescribing 
decisions to one named person was suggested to be of high 
importance. Despite identification of these barriers and 
facilitators, the limited evidence available results in many 
remaining uncertainties regarding key areas relevant to the 
implementation of ACB reduction in practice.
Comparison to a review of the broader concept of ‘depre-
scribing’ [16] reveals many similarities in findings. In the 
review by Anderson et al. [16] health professionals’ reluc-
tance to engage with the deprescribing of inappropriate 
Fig. 2  An illustration of barriers and facilitators of ACB reduction from the perspective of healthcare professionals
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medications was an overarching theme. Similar to the pre-
sent review, a number of reasons were reported to explain 
this; conflict with patients, carers or other healthcare profes-
sionals, concerns about impact on workload, concerns about 
losing credibility, risks to patient’s health, lack of knowledge 
and confidence, and poor communication with other health-
care professionals often resulting in low motivation to tackle 
deprescribing [16]. Conversely, beliefs that deprescribing 
was beneficial for patients, concerns about risks of continu-
ation, and confidence to deviate from guidelines were all 
reported to help enable healthcare professional deprescribing 
[16]. Those with experience of deprescribing and who had 
undergone deprescribing training demonstrated more posi-
tive attitudes towards deprescribing [16].
Unlike Anderson et al. [16] the present review identified 
little about patient resistance. A review of barriers and facili-
tators towards deprescribing from the patient’s perspective 
demonstrated that patients do generally support deprescrib-
ing if they understand that it is appropriate for them [18]. 
Recent surveys suggest that over three quarters of patients 
and carers are willing to stop at least one medication if a 
healthcare professional said that it was the best course of 
action [37, 38]. Yet, health professionals perceive patient 
willingness to reduce or stop medications as low [39, 40]. 
One explanation for this mismatch may be the lack of patient 
involvement in medication reviews [40]. Despite believing 
that patients should be involved in medication reviews, GPs 
and pharmacists reported that it was too resource heavy to do 
so [40]. Concerns that deprescribing reduced health profes-
sionals’ credibility have also been raised [16]. However, this 
was not substantiated in a recent patient-centred deprescrib-
ing intervention [41]. Perhaps lack of engagement of patients 
in the process explains any perceived or realised resistance; 
it is not the change that patients may resist, but the lack of 
their involvement.
Conflict arising from collaborations with other profes-
sionals, and the system and organisational barriers, are 
commonly reported in the deprescribing literature [16, 39, 
40]. It is evident that a clear process, which fits with exist-
ing practices, with shared acceptance and understanding, is 
important. It remains unclear how this is best achieved. One 
study proposes a 5-step patient-centred model [42], however 
the model lacks detail as to how it would be implemented 
in clinical practice. Only when the challenges are clearly 
delineated and working solutions found and implemented, 
can such a model be adopted into routine care.
ACB reduction as a research field is in early develop-
ment. This may explain the limited number of studies 
identified and data available for synthesis. However, inter-
ventions in this area show promise [15]. Further research 
into the complex nature of ACB reduction, along with 
important issues surrounding implementation, will allow 
these benefits to be realised in clinical care, which can 
benefit the health and well-being of a number of patients. 
Several critical research questions have been identified by 
this review to provide a starting point for future research 
in this newly emerging field tackling ACB. These include:
• Who should be involved and have responsibility for 
ACB reduction?
• How can inter-professional collaboration be improved?
• How can ACB reduction be integrated with clinical 
judgement?
• How might ACB reduction be adapted for different 
health care systems which involve multiple providers?
This review involved a comprehensive search strategy and 
was conducted in accordance with methodological rec-
ommendations. All study processes were conducted by 
two independent reviewers (e.g. screening, data extrac-
tion, analysis, quality assessment) and an appropriate 
theoretical framework of analysis was applied to enhance 
understanding of implementation issues. This is in line 
with MRC recommendations for understanding complex 
interventions [20]. However, our review is limited by very 
few studies, the lack of patient or carer perspectives and 
the quality of included studies. Only two eligible studies 
were identified, one of which was of poor quality and high 
risk of bias, with limited qualitative data for analysis. Both 
studies exclusively focused upon care for older people. 
One study [35] presented qualitative data which appeared 
to be collected opportunistically rather than planned quali-
tative analysis. Reporting of details regarding the methods 
of collecting and analysing the qualitative data were poor, 
resulting in this study being considered very low quality. 
Presentation of results was also limited in this study. As a 
consequence, our findings are limited in their breadth and 
depth, and restricted to the perspectives of healthcare pro-
fessionals, employed in the Australian healthcare system, 
towards anticholinergic reduction amongst older people.
Conclusion
Despite limited studies this review identified several 
important barriers and facilitators to ACB reduction which 
require further exploration to enhance the implementa-
tion of future ACB reduction interventions. The distinct 
lack of exploration of patient and carer perceptions risks 
the development of interventions which are not person-
centred, impeding successful implementation. This review 
identifies several important areas for future research which 
need to be undertaken to enable the development of suc-
cessful ACB reduction interventions.
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